Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 11/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12600975 | 1.00 | TLR4 (0.45) | TLR4MAPK1LY96MCHR1SSTR1 | |
| SCHEMBL12371590 | 0.93 | TLR4 (0.39) | TLR4MAPK1LY96 | |
| SCHEMBL13296761 | 0.93 | TLR4 (0.39) | TLR4MAPK1LY96 | |
| SCHEMBL12560697 | 0.88 | TLR4 (0.46) | TLR4MAPK1LY96 | |
| SCHEMBL12560681 | 0.88 | TLR4 (0.46) | TLR4MAPK1LY96 | |
| SCHEMBL12762967 | 0.88 | TLR4 (0.46) | TLR4MAPK1LY96 | |
| SCHEMBL12560728 | 0.88 | TLR4 (0.46) | TLR4MAPK1LY96 | |
| SCHEMBL4191756 | 0.88 | TLR4 (0.46) | TLR4MAPK1LY96MCHR1SSTR1 | |
| SCHEMBL12763047 | 0.87 | MAPK1 (0.49) | TLR4MAPK1LY96 | |
| SCHEMBL4209695 | 0.87 | TLR4 (0.43) | TLR4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | TLR4 24/4885MAPK1 2123/4885LY96 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.